Mallinckrodt Scholar Award
Internal deadline: December 4, 2018
The Edward Mallinckrodt, Jr. Foundation is a private foundation that funds basic biomedical research in St. Louis and throughout the United States. The mission of the Foundation is to support early stage investigators engaged in biomedical research that has the potential to significantly advance the understanding, diagnosis, or treatment of disease. Each year, institutions are invited to submit candidates for the Mallinckrodt Scholar Award. The institutions are selected by the Mallinckrodt Board based on their history of quality grant applications and award selection.
Eligibility & Requirements:
Internal Nomination Process:
Interested applicants should submit the following documents to firstname.lastname@example.org:
Internal deadline: December
Instrument Acquisition: An MRI acquisition
proposal is characterized by a purchase or upgrade of a generally available,
yet sophisticated, instrument with little or no modification and risk.
Instrument Development: A development
proposal should demonstrate the need for a new or extensively upgraded
instrument with new performance, enabling enhanced or potentially transformative
research opportunities, open up new areas of research and research training
and/or have potential as a commercial product.
Any MRI proposal may request support for
either the acquisition or development of a research instrument.
Eligibility & Requirements:
No application deadline
The Michael J. Fox Foundation is sponsoring a $2 million prize to the first team to develop a viable selective alpha-synuclein PET tracer and agree to make that tracer available broadly.
The ability to image alpha-synuclein deposition
in the brain would be a game-changing achievement for the Parkinson's
disease (PD) field. The accumulation of aggregated alpha-synuclein is
a pathological hallmark of PD and a priority target for drug development
given its hypothesized contribution to neurodegeneration. In vivo imaging
of alpha-synuclein pathology could be useful as a biomarker of the presence
of disease and disease progression and as a pharmacodynamic tool for
drug development. With this prize, the Foundation seeks to attract research
teams and accelerate momentum to speed the development of such a tracer.
Contestants: Anyone is eligible for
the prize who agrees to all contest rules. Contestants may be MJFF funded
or not and can be from either academia or industry.
Criteria for winning: The winning contestant
must demonstrate that the radiotracer binds with relatively high selectivity
to alpha-synuclein according to pre-specified criteria and must demonstrate
proof-of-concept in human subjects, including people with Parkinson's
disease and/or another synucleinopathy. See below for more details on
Timeline: There is no deadline
for submissions. The $2 million award will be issued to the first
contestant who submits compelling evidence of a viable selective tracer
and agrees to its widespread use. If no award is given by mid-2018,
The Michael J. Fox Foundation will evaluate the state of the field and
utility of such a prize.